A Randomized Controlled Trial: Efficacy of Dexamethasone Versus Methylprednisolone Intratympanic Injection for Primary Treatment of Idiopathic Sudden Sensorineural Hearing Loss

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210607002

Enrollment

Registered

2021-06-07

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic sudden sensorineural hearing loss in adult Sudden hearing loss, sudden deafness

Interventions

Intratympanic Dexamethasone 5 mg/ml 0.4-0.8 ml for 4 times in 2 weeks,Intratympanic Methylprednisolone 40 mg/ml 0.4-0.8 ml for 4 times in 2 weeks

Active Comparator Drug,Experimental Drug

Dexamethasone,Methylprednisolone

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. New patient age 18-80 years old with diagnosed as sensorineural hearing loss which decrease in hearing of 30 or more decibels affecting at least 3 consecutive frequencies and occurs within a 72-hour window 2. Only affects in one ear 3. No previous corticosteroids 4. Presents within 2 weeks of symptom onset

Exclusion criteria

Exclusion criteria: 1. Known cause of hearing loss 2. Fluctuated hearing level or history of previous hearing loss

Design outcomes

Primary

Measure	Time frame
Hearing level At 1 and 12 weeks after completion Audiogram	—

Secondary

Measure	Time frame
Side effects At time of visit Pain score	—

Countries

Thailand

Contacts

Public ContactSupaksarun Cheewasukanont

Department of otolaryngology, faculty of medicine, Chulalongkorn university

bluebell1418@gmail.com0863611817

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026